HE4 in the Diagnostic Approach of Endometrial Cancer in Patients With Postmenopausal Bleeding
-
- STATUS
- Recruiting
-
- End date
- Sep 1, 2022
-
- participants needed
- 100
-
- sponsor
- Nantes University Hospital
Summary
This study aims to explore the sensitivity of an innovative marker, HE4, in the diagnosis approach of endometrial cancer in case of postmenopausal bleedings.
Description
Endometrial cancer is the most common pelvic gynecological cancer in France, ranking 5th among cancers in women in terms of incidence.
The most frequent symptom is post-menopausal bleeding and is one of the primary reasons for consultation in gynecological emergencies.
The diagnosis of endometrial cancer is made by histological analysis of endometrial tissue taken during a surgical intervention. The latter is mostly reassuring.
These interventions are often performed in mild situations and there is currently no element to be sufficiently reassuring to avoid surgery.
At present, there is no biological marker used in current practice. In the population of patients with post-menopausal bleeding requiring surgical exploration for diagnosis, the pathology results are often reassuring. These procedures could have been avoided, especially as these patients often have numerous co-morbidities and these surgeries are therefore more risky. The appearance of a new tumour marker could be useful in the management of these patients and avoid many unnecessary and risky surgeries
This study aims to explore the sensitivity of an innovative marker, HE4, in the diagnosis approach of endometrial cancer in case of postmenopausal bleedings.
Details
| Condition | Menopause, ca 125, Disorder of uterus NOS, Postmenopause, Endometrial Cancer, Cancer Biomarker, Vaginal Bleeding, Uterine Cancer, Endometrial Carcinoma, ca-125, cancer antigen 125, CA-125 Antigen, uterine bleeding, Uterine Disorders, Post Menopause, Hemorrhage |
|---|---|
| Treatment | Patients with Post menopausal bleeding, CA125 and HE4 assays |
| Clinical Study Identifier | NCT04867109 |
| Sponsor | Nantes University Hospital |
| Last Modified on | 27 September 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer